I smell IPO
Neil J. Campbell President & CEO at Helomics Corporation Washington D.C. Metro AreaVenture Capital & Private Equity Current Helomics Corporation, HealthCare Royalty Partners, University of Liverpool Previous SuperNova Diagnostics, Inc., CureKids - Child Health Research Institute, New Zealand Government-NZTE Education University of Liverpool Recommendations 50 people have recommended Neil J. Websites Company Website 500+ connections Join LinkedIn & access Neil J.'s full profile. It's free! As a LinkedIn member, you'll join 300 million other professionals who are sharing connections, ideas, and opportunities. •See who you know in common •Get introduced •Contact Neil J. directly View Neil J.'s Full Profile Helomics Corporation Background Summary EXECUTIVE PROFILE A global C-level entrepreneurial executive with 25+ years of success building public and private businesses in science & technology sectors with a strong focus on the life sciences through the commercialization of over 275 products and services. Leveraged executive career with private VC/PE international investment fund experience as general partner and advisor. Range of involvement from start-ups to Fortune 500 providing leadership in turnarounds, stagnant growth, emerging-growth and developing country scenarios. Washington D.C. and London, U.K. based. UNIQUE VALUE PROPOSITION • Big picture thinking, highly analytical, adaptable, agile, dynamic, motivating and passionate serial entrepreneur. • Start-up, turnaround, growth phase and commercial execution expert. • Capital market experience from seed to IPO with over $300M directly raised and involved in road show teams for IPOs totaling > $1B. • Deep technical aptitude with hands-on ability coupled with seasoned and diversified business leadership. • Scholar-practitioner, author and speaker on innovation, entrepreneurship and capital appreciation methods for science & technology commercialization. Advisor to HNWI, FOs, VC and PE funds with board practice advisory services. Experience President & CEO Helomics Corporation September 2014 – Present (6 months)|Greater Pittsburgh Area Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. We are dedicated to improving patient outcomes by utilizing a proprietary set of laboratory platforms and our product science as a service commercialization model to allow physicians to characterize malignant tumors. Our novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual's cancer. Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com HealthCare Royalty Partners Advisor & Operating Partner HealthCare Royalty Partners 2014 – Present (1 year)|Stamford, Connecticut About HealthCare Royalty Partners HealthCare Royalty Partners ("HC Royalty") is a $3.0+ billion global healthcare investment firm. HC Royalty invests primarily in commercial stage healthcare assets that have significant clinical value, strong barriers to entry and that are marketed by some of the world’s largest pharmaceutical companies. Over the past decade, the senior investment team has completed more than 60 royalty investments valued in excess of $2.5 billion. Our philosophy is simple. Identify compelling investment opportunities that will generate significant long-term value for our partners and our investors. We currently manage over $3.0 billion in capital across four investment funds. For more information, visit www.healthcareroyalty.com. Senior Research Fellow University of Liverpool 2010 – Present (5 years)|Liverpool, United Kingdom Consultant Advisory Board, Scottish Government- GlobalScots 2008 – Present (7 years)|Global Scotland has always made its presence felt in the world of international business, earning an impressive reputation for Innovation, drive and entrepreneurial expertise. GlobalScot Advisors seek to develop and expand Scotland's standing in the global business community by utilising the talents of leading Scots, and of people with an affinity for Scotland, to establish a worldwide network of individuals who are outstanding in their field. Since the formation of GlobalScot in 2001, we have already achieved significant results with many Scottish companies, proving that GlobalScots can - and do - make a real difference to the Scottish economy. Mosaigen, LLC Executive Chairman Mosaigen, LLC 2004 – Present (11 years) Mosaigen, LLC was founded in 2004 as a global technology development corporation specializing in the life sciences, ICT and Cleantech industries. Our portfolio company projects are globally oriented. The company is headquartered in the Greater Wash D.C. area with offices in U.S. and affiliate groups in Europe and Asia. Our proprietary venture creation/acceleration model "reverse startup" approach combines assets, people and money into new or existing entities to develop well run, capital efficient, lower risk companies. We work with leading universities and entrepreneurs to turn their dreams into commercially viable products and technologies. Our focus is: - Nanotechnology & Material Sciences - Life Sciences (Pharma, Device, Diagnostics, Research, OTC/CPG) - ICT (High performance computing, Web 2.0, Machine Learning, Pattern Recognition/Dynamic Scaffolding, Virtualization platforms, Simulation, Physics Engines and New Media) - Clean/Green Tech (Solar, Wind, Smart Software, Materials, renewable Energy, non-food stock biofuels & ISBEs) You can reach me at my email: ncampbell@mosaigen.com SuperNova Diagnostics, Inc. President & CEO, Co-Founder SuperNova Diagnostics, Inc. 2009 – 2013 (4 years)|Wash DC, London, Hong Kong About SuperNova Diagnostics, Inc. SuperNova is a early commercial stage diagnostics company with a proprietary diagnostics platform that greatly enables point-of-care in human health and point-of-use for non-human health applications. A powerful proprietary nanochemistry, AmpCrystal™, can delivery novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. Can also be utilized in a wide range of diagnostic formats (disposable cartridges, lateral flow, microtitre, arrays, OEM, etc.) CureKids - Child Health Research Institute Chairman CureKids - Child Health Research Institute 2006 – 2013 (7 years) CureKids™ is an innovative children’s charity investing in children’s lives by accelerating science and technology and catalytically bringing together the social entrepreneur with the socially-minded donor to bring about change in how philanthropic giving can make a difference in commercializing products & services in life sciences, IT and education to eradicate disorders and diseases in children. CureKids was established more than 30 years ago to address the lack of research into life-threatening childhood illness in New Zealand and has since become an international organization. Since then, the organization has invested more than $30 million in medical R&D and commercialization. This social investments has helped save hundreds of young lives and has improved the quality of life for thousands of children around the world. Our model is based upon the most leading edge venture philanthropy strategies for social investment. New Zealand Government-NZTE Advisory Board New Zealand Government-NZTE 2000 – 2013 (13 years) The Advisory Board of Beachheads programmes helps New Zealand and NZ-Associated companies succeed domestically and internationally by providing access to private sector advisors, direct investments and their top quality international networks. Visiting Scholar, Bionanotechnology & Chemistry Hong Kong University of Science & Technology (HKUST) 2010 – 2012 (2 years)|Hong Kong, Hong Kong Ranked #1 in Asia and in top 20 in combined world rankings for universities science & technology Endeavour Capital General Partner Endeavour Capital 2006 – 2011 (5 years) Established in 1999, Endeavour Capital a leading Asia/Pacific investment company with a focus on developing globally competitive companies based on science and technology innovations. Endeavour has made investments across biotechnology, software, cleantech, healthcare and medical device sectors. The Endeavour Team is comprised of experienced entrepreneurs and investment professionals, each having key involvement in building and exiting at least one significant company in Asia/Pacific or USA. Our model is to provide portfolio companies with significant operational, commercial and technical resources, complemented with capital. In order to assist with international growth plans, the Endeavour Capital managers form a partnership with the founders and key staff to maximize a company's worldwide opportunities. We can make investments in Asia/Pacific, EU zone, Gulf Region and look to U.S.A. for investment deals, limited partners and for us to locate promising companies. Johns Hopkins University Adjunct Professor Carey Graduate School of Business Johns Hopkins University 2004 – 2010 (6 years) Adjunct Professor (practitioner faculty)of Business & Entrepreneurship in the Carey Graduate School of Business in conjunction with joint program with Johns Hopkins School of Medicine teaching courses in corporate & organizational finance, venture creation topics and entrepreneurship/leadership. President & CEO/COO EntreMed, Inc. 2001 – 2004 (3 years) EntreMed is a public (NASDAQ), clinical-stage (Phase II) biopharmaceutical company developing therapeutics for disease indications of cancer, ophthalmology, cardiovascular, dermatology, bone, inflammation and woman's health. • (All public information available through SEC filings) Appointed principal chief executive (acting CEO) tasked with saving the company when only three months of available cash remained. Settled major litigation with Celgene & Abbott, NASDAQ delisting notification and over $15M in debt over-hang. • Proactively orchestrated financial and corporate transactions totaling $150.2M over 3 year period. • Negotiated out-license and assignment of rights for Angiostatin & Endostatin proteins (Phase II); gene therapy eye deal with Oxford BioMedica in UK;Phase I deal Celgene Corporation in December, 2002( deal was completed with only 4.5 days of cash on hand)Thalidomide analogs;Allergan for ophthalmologic pharmaceuticals in January 2002. Celera Genomics Senior Director, Commercial Development Celera Genomics 1999 – 2001 (2 years) Worldwide commercial director for Celera's Discovery e-Commerce web-based portal and supporting genomic and proteomic database products and services. Position combined sales & marketing with original business development activities with full P&L in establishing new business opportunities and custom products in drug discovery, supporting clinical drug programs and disease evidence-based programs. Worked with various groups to help setup and establish activities in Japan for Celera Japan and interactions with Japanese Pharma & Biotech companies. Also signed first country-wide deal with Australia and first University Partnership with Vanderbilt University. Director of Worldwide Business Cell & Molecular Biology Life Technologies 1996 – 2000 (4 years) Global Business Director for Cell & Molecular Biology business, services and e-commerce with full P&L responsibilities. Established or expanded sales revenues and offices in North America, Europe, Middle East, India, South East Asia, Japan and Oceania. Our business group created, developed and launched over 40 new products during tenure of position to include the Platinum Molecular Biology line. General Manager & Program Director IGEN International (Now Roche) 1994 – 1996 (2 years) GM for small-scale biosensor technologies for analysis of proteins, DNA and RNA. Applications were high throughput drug screening, point of care diagnostic testing, point of use diagnostics for food, beverage and biosecurity and central laboratory testing utilizing electrochemiluminence self-contained sensors. Worked with strategic partners, Eisai Pharma (Japan), Boerhringer Mannheim (Germany) and Perkin-Elmer/ABI (United States) for NASBA DNA. Abbott Laboratories Various Sales & Marketing, Business Development Abbott Laboratories 1988 – 1993 (5 years) Various Sales & Marketing, business development positions in the Diagnostics Division (ADD) and special program division in marketing with the Pharmaceutical and Hospital products divisions with the physician office marketplace Locations were New York City Area, New England (Boston Region) and headquarters in North Chicago (Abbott Park), Illinois. United States Air Force Captain CCM Commander United States Air Force 1982 – 1987 (5 years) Honorable Discharge. Top Secret (BI) Clearance for positions. Worked within Eight Air Force & Strategic Air Command with nuclear engineering/intercontinental ballistic missile systems commander. Staff instructor in Air Force Titan Missile Systems. Volunteer Experience & Causes Chairman KidsRgenius January 2010|Children A Children's charity in solving community-based problems through social entrepreneurship whereby the entrepreneurs are kids in the community solving local problems that can be made portable and exported to other communities around the world. the children are teamed with adult entrepreneurs and local universities to learn life, business and entrepreneurial skills. the goal is to solve problems today from a kid's perspective and hopefully impact the lives of the community, but also turn more kids into impactful adult entrepreneurs. Patents Methods of Triggering Activation of Encapsulated Signal-Generating Substances and Apparatus Utilising Activated Signal-Generating Substances(Link) United States 8,586,387 Issued November 19, 2013 Methods of triggering activation of encapsulated signal-generating substances and apparatus utilising activated signal-generating substances Skills Biotechnology Corporate Development Start-ups Technology Transfer Mergers Strategy Development Business Strategy Entrepreneurship Strategic Partnerships Due Diligence International Business Entrepreneur Management Consulting Strategic Planning Executive Management See 35+ Education University of Liverpool University of Liverpool Doctorate in Business Adminstration, Science & Technology - International Finance 2010 – 2015 Webster University (AT) M.B.A., International Business 1985 – 1987 Webster University Webster University M.A, Management Sciences 1983 – 1985 Norwich University Norwich University BS, Business Administration 1978 – 1982 Groups